<DOC>
	<DOCNO>NCT01565746</DOCNO>
	<brief_summary>This uncontrolled , open-label , non-randomized Phase I study investigate safety , biodistribution , radiation dosimetry pharmacokinetics single dose BAY88-8223 Japanese patient castration-resistant prostate cancer bone metastasis .</brief_summary>
	<brief_title>Safety , Biodistribution , Radiation Dosimetry Pharmacokinetics Study BAY88-8223 Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Male â‰¥ 20 year age Histologically cytologically confirm adenocarcinoma prostate Presents least 2 bone metastasis , confirm scintigraphic imaging within previous 4 week Patients fail initial hormonal therapy use either orchiectomy Gonadotropin release hormone ( GnRH ) agonist combination antiandrogen must first progress antiandrogen withdrawal prior eligible . The minimum timeframe document failure antiandrogen withdrawal four week Progressive castration resistant metastatic disease Castrate level testosterone ( &lt; 50 ng/dL ) , treatment maintain castrate level testosterone must continue Has receive investigational drug 4 week schedule receive one 8 week study drug administration . Has receive chemo , immuno , radiotherapy within last 4 week prior entry study , recover acute adverse event result therapy Has receive prior hemibody external radiotherapy Has need immediate external radiotherapy Has receive systemic radiotherapy radium223 , strontium89 , samarium153 , rhenium186 rhenium188 treatment bony metastasis within last 24 week prior administration study drug When receive bisphosphonates , change dose within 4 week administration study drug</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>BAY88-8223</keyword>
	<keyword>radium-223 dichloride</keyword>
	<keyword>prostate cancer</keyword>
</DOC>